Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus

INTRODUCTION: The clinical benefits of treating patients with type 2 diabetes mellitus (T2DM) with fixed-ratio combination of insulin iGlar (iGlar) plus lixisenatide (iGlarLixi) were demonstrated in clinical trials and real-world evidence studies; however, its cost impact to healthcare payers is unk...

Descripción completa

Detalles Bibliográficos
Autores principales: Ken-Opurum, Jennifer, Srinivas, Sistla S. S., Jain, Divya, Shah, Tejaswinee, Samnaliev, Mihail, Dex, Terry, Charland, Scott, Revel, Andrew, Preblick, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597971/
https://www.ncbi.nlm.nih.gov/pubmed/37801225
http://dx.doi.org/10.1007/s13300-023-01477-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597971/
https://www.ncbi.nlm.nih.gov/pubmed/37801225
http://dx.doi.org/10.1007/s13300-023-01477-3

Ejemplares similares